ArticleACS applied nano materials2024
Combination Chemical and Mechanical Tumor Immunomodulation Using Cavitating Mesoporous Silica Nanoparticles.
Article in ACS applied nano materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Shape-Programmable Particles from Photocurable Poly(β-Amino Esters) for Drug Delivery Applications.Advanced functional materials · 2026Article
- Revisiting Colloid Theory for Biomedicine: Reconciling Simple Models in Complex Environments.ACS nano medicine · 2026Article
- Nanoplatforms-Enhanced High-Intensity Focused Ultrasound for Cancer Immunotherapy.International journal of nanomedicine · 2026Review
- Particle Shape Modulates the Function of Adoptive Macrophage Transfers.Advanced healthcare materials · 2025Article
- Transport of Adoptive Cell Transfers With Magnetic Helical Microrobots.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Ionic Liquid-Mediated Delivery of Ruxolitinib to Skin Using an Adhesive Topical Hydrogel System.Advanced healthcare materials · 2025Article
- Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers.Advanced materials (Deerfield Beach, Fla.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Combinatorial methods to repolarize tumor-associated macrophages from anti-inflammatory to pro-inflammatory phenotypes offers a promising route for cancer immunotherapy. However, most studies examine biochemical combinations alone. Therefore, we studied simultaneous chemical and mechanical stimuli as orthogonal cues for enhanced immunomodulation. We engineered the surfaces of hydrophobically functionalized mesoporous silica nanoparticles (F108-hMSNs) to encapsulate the immunomodulator resiquimod and kill cancer cells through high-intensity focused ultrasound (HIFU)-mediated inertial cavitation, releasing damage-associated molecular patterns (DAMPs) for prolonged macrophage stimulation. The HIFU doses alone did not affect cells, but in combination with F108-hMSNs, achieved significantly higher cancer cell death and DAMP generation. Inflammatory markers (CD86, MHC II, iNOS) were upregulated in tumor-associated-like macrophages treated with F108-hMSNs in the presence of HIFU and experienced the greatest inflammatory phenotypic shift of all conditions tested. This work suggests that chemical and mechanical activation facilitated by engineered nanoparticles offer a promising treatment against immunologically cold tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.